title: [Effectiveness of vaccination against hepatitis B in HIV infected children].
abstract: OBJECTIVE
  The aim of the study was to evaluate hepatitis B vaccination effectiveness in HIV infected children.
  
  
  METHODS
  45 children vertically infected with HIV who received hepatitis B vaccination were evaluated. Anti-HBs antibodies were assayed to established vaccination efficiency and were repeated every 6-12 months. No-responders received the next vaccination schedule with doubled dose. Children with antibody levels < 100 IU/ml were boostered. All the children have been receiving HAART.
  
  
  METHODS
  35/45 (77,8%) children had anti-HBs antibodies > 100 IU/ml, including 20 with anti-HBs antibodies > or = 1000 IU/ml (32 children without immunodeficiency, 2 with moderate and 1 with severe immunodeficiency). Anti-HBs level 8-100 IU/ml was observed in 6/46 (13,3%) children (5 children without immunodeficiency and 1 with severe immunodeficiency). 4/46 (8.9%) children had no anti-HBs antibodies (2 children without immunodeficiency, 1 with moderate and 1 with severe immunodeficiency).
  
  
  CONCLUSIONS
  In HIV infected children anti-HBs antibodies should be assayed to establish hepatitis B vaccination efficiency and repeated every 6-12 months.
authors.affiliation: Klinika Chorób Zakaźnych Wieku Dzieciecego Akademii Medycznej w Warszawie.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Ołdakowska
authors.forename: Magdalena
authors.initials: M
authors.lastname: Marczyńska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Szczepańska-Putz
authors.forename: Barbara
authors.initials: B
authors.lastname: Kowalik-Mikołajewska
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood* / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D032541:Mass Vaccination; D011044:Poland
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines